Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Eye drops can help soothe dry eyes by giving them much-needed ... Buy now £8.99, Holland & Barrett Ocuvite Complete, Eye Supplement Capsules, by Bausch + Lomb From one of the world's leading eye ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

The global ophthalmic eye drop market is poised for steady growth over the next decade. The market, which was valued at USD ...

Bloomberg News Now is a comprehensive audio report on today's top stories. Listen for the latest news, whenever you want it, covering global business stories around the world.

Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned ...